Immuron Limited · ASX:IMC
Immuron — Investor Presentation (July 2026)
11 slides from Immuron's investor presentation, Jul 27, 2026
Slide 1: Investor Presentation
27 July 2026 Steven Lydeamore Chief Executive Officer Investor Presentation NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: Immuron: Australian integrated biopharmaceutical company
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases Research & Development 2 pipeline assets to be partnered for development and commercialization Global footprint Au
Slide 4: Executive summary: FY Sales Results
4 FY 26 Sales Results FY26 Global Sales Revenue of A$7.7 million up 6% on prior year FY26 Australian Sales of A$5.8 million, up 10% FY26 U.S. Sales of A$1.8 million, up 7%; up 13% in USD FY26 Canada Sales of A$0.2 million, down 55% Executive summary Two commercial products: Travelan® (traveler’s dia
Slide 5: Continued strong sales growth
5 Continued strong sales growth Global + FY2026 AUD$7.7 million up 6% on prior year Australia + FY2026 AUD$5.8 million up 10% on prior year North America + FY2026 AUD$1.9 million down 5% on prior year + USA FY2026 AUD$1.8 million up 7% on prior year; up 13% in USD + Canada FY2026 AUD$0.2 million dow
Slide 6: Immuron strategic reset provides clearer path to profitability
6 Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM - 124E and IMM - 529 for development and commercialization. • IMM - 124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s diarrhea
Slide 7: A First-in-Class Triple-Action CDI Biologic
7 IMM - 529: A First - in - Class Triple - Action CDI Biologic The Opportunity : IMM - 529 is an oral, non - systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM - 529 eliminates the
Slide 8: The Disease: C. difficile and market opportunity
The Disease: C. difficile is the leading cause of healthcare - associated infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild - to - moderate : Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PMC) : Colon wall plaques • Fulminant CDI
Slide 9: Deal Potential: comparable licensing transactions
9 IMM - 529 Deal Potential Status update (as of March 2026) Stage at deal Financial terms (public) Licensed Asset Licensee / Acquirer Licensor / Asset Owner Year FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction. ( U
Slide 10: Why Invest in Immuron?
10 Why Invest in Immuron? • Broad Platform Utility: This isn't a one - trick pony. The technology can be applied to a range of infectious diseases, creating a deep pipeline of potential drug candidates. • High Barrier to Entry: The company’s proprietary vaccination protocols and the "hyper - immune"
Slide 11: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: